292 related articles for article (PubMed ID: 1374810)
41. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
Boudet F; Girard M; Theze J; Zouali M
Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
[TBL] [Abstract][Full Text] [Related]
42. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
43. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
44. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
[TBL] [Abstract][Full Text] [Related]
45. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
46. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
[TBL] [Abstract][Full Text] [Related]
47. Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.
König RR; Flory E; Steidl S; Neumann J; Coulibaly C; Holznagel E; Holzammer S; Norley S; Cichutek K
J Virol; 2002 Nov; 76(21):10627-36. PubMed ID: 12368305
[TBL] [Abstract][Full Text] [Related]
48. Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.
Etemad-Moghadam B; Sun Y; Nicholson EK; Karlsson GB; Schenten D; Sodroski J
J Virol; 1999 Oct; 73(10):8873-9. PubMed ID: 10482646
[TBL] [Abstract][Full Text] [Related]
49. Neutralizing monoclonal antibody against a external envelope glycoprotein (gp110) of SIVmac251.
Matsumi S; Matsushita S; Yoshimura K; Javaherian K; Takatsuki K
AIDS Res Hum Retroviruses; 1995 Apr; 11(4):501-8. PubMed ID: 7632464
[TBL] [Abstract][Full Text] [Related]
50. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
51. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection.
Eda Y; Murakami T; Ami Y; Nakasone T; Takizawa M; Someya K; Kaizu M; Izumi Y; Yoshino N; Matsushita S; Higuchi H; Matsui H; Shinohara K; Takeuchi H; Koyanagi Y; Yamamoto N; Honda M
J Virol; 2006 Jun; 80(11):5563-70. PubMed ID: 16699037
[TBL] [Abstract][Full Text] [Related]
52. Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination.
McBride BW; Corthals G; Rud E; Kent K; Webster S; Cook N; Cranage MP
J Gen Virol; 1993 Jun; 74 ( Pt 6)():1033-41. PubMed ID: 7685372
[TBL] [Abstract][Full Text] [Related]
53. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.
Burns DP; Collignon C; Desrosiers RC
J Virol; 1993 Jul; 67(7):4104-13. PubMed ID: 8510218
[TBL] [Abstract][Full Text] [Related]
54. Characterization of primary isolate-like variants of simian-human immunodeficiency virus.
Crawford JM; Earl PL; Moss B; Reimann KA; Wyand MS; Manson KH; Bilska M; Zhou JT; Pauza CD; Parren PW; Burton DR; Sodroski JG; Letvin NL; Montefiori DC
J Virol; 1999 Dec; 73(12):10199-207. PubMed ID: 10559336
[TBL] [Abstract][Full Text] [Related]
55. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
56. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
[TBL] [Abstract][Full Text] [Related]
57. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
Schlienger K; Montefiori DC; Mancini M; Rivière Y; Tiollais P; Michel ML
J Virol; 1994 Oct; 68(10):6578-88. PubMed ID: 7521918
[TBL] [Abstract][Full Text] [Related]
58. Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition.
Vahlne A; Horal P; Eriksson K; Jeansson S; Rymo L; Hedström KG; Czerkinsky C; Holmgren J; Svennerholm B
Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10744-8. PubMed ID: 1961741
[TBL] [Abstract][Full Text] [Related]
59. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
Edinger AL; Ahuja M; Sung T; Baxter KC; Haggarty B; Doms RW; Hoxie JA
J Virol; 2000 Sep; 74(17):7922-35. PubMed ID: 10933700
[TBL] [Abstract][Full Text] [Related]
60. Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1).
Neurath AR; Strick N
Mol Immunol; 1990 Jun; 27(6):539-49. PubMed ID: 1696353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
